FSPHX | HGHRX | FSPHX / HGHRX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 43 years | 18 years | - |
Gain YTD | 4.590 | 1.952 | 235% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 7.41B | 986M | 752% |
Annual Yield % from dividends | 0.00 | 0.00 | - |
Returns for 1 year | 15.74 | 10.62 | 148% |
Returns for 3 years | -12.43 | -17.00 | 73% |
Returns for 5 years | 14.41 | 1.11 | 1,293% |
Returns for 10 years | 30.51 | -0.47 | -6,492% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
SROI | 29.81 | N/A | N/A |
Calamos Antetokounmpo Global Sus Eqs ETF | |||
REVS | 26.24 | -0.01 | -0.05% |
Columbia Research Enhanced Value ETF | |||
TLH | 101.70 | -0.16 | -0.16% |
iShares 10-20 Year Treasury Bond ETF | |||
CZA | 109.48 | -0.45 | -0.41% |
Invesco Zacks Mid-Cap ETF | |||
ROM | 67.96 | -3.57 | -4.99% |
ProShares Ultra Technology |